The positive clinical progress on CHAPTER-3 enrollment and maintained NDA timeline provide near-term catalysts, but the significant increase in R&D spending and widening net loss could pressure the balance sheet. Traders should monitor cash burn rate and upcoming topline data in Q3 2026 as key value drivers.
Price Chart
Executive Summary
Pharvaris reported its 2025 financial results and provided updates on its clinical development pipeline. Key developments include completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR with topline data expected in Q3 2026, continued progress on the NDA submission for deucrictibant IR in 1H 2026, and ongoing enrollment in the CREAATE study for AAE-C1INH. The company reported €291.7 million in cash as of December 31, 2025, with full-year R&D expenses increasing to €124.5 million.
Key Facts
- Enrollment completed in CHAPTER-3 pivotal study for deucrictibant XR; topline data expected in Q3 2026
- NDA submission for deucrictibant IR remains on track for 1H 2026
- Enrollment ongoing in CREAATE pivotal study for AAE-C1INH
- Cash and cash equivalents of €291.7 million as of December 31, 2025
- Full-year 2025 R&D expenses were €124.5 million, up from €98.6 million in 2024
- Full-year 2025 net loss was €175.7 million, compared to €134.2 million in 2024
Financial Impact
R&D expenses increased 26.3% year-over-year to €124.5 million, while net loss widened to €175.7 million from €134.2 million in 2024. Cash position increased to €291.7 million from €281 million at end of 2024.
Risk Factors
- Increased R&D spending could accelerate cash burn
- Clinical trial results may not meet expectations
- Regulatory approval timelines could slip
- Competition in HAE treatment market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001830487-26-000012 |
| Document: pr_fin_results_2025.htm | 0001830487-26-000012 |
| Document: 0001830487-26-000012-index-headers.html | 0001830487-26-000012 |
| Document: 0001830487-26-000012-index.html | 0001830487-26-000012 |
| Document: 0001830487-26-000012.txt | 0001830487-26-000012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access